collaboration with Syros Pharmaceuticals, Inc., to discover,
develop and commercialize novel therapies for SCD and beta
thalassemia based on the induction of fetal hemoglobin. This gives
us the potential to advance other innovative approaches into
clinical studies that have the potential to meaningfully improve
the lives of people with SCD. We also continue to work in our own
labs – where Oxbryta was discovered and developed – on potential
next generation small molecule product candidates.
Bringing Hope to SCD Patients Globally
While our current focus is getting Oxbryta to patients in the
United States, we are also committed to addressing SCD around the
world. It is a major global public health issue, with millions of
people of African, Middle Eastern and South Asian descent suffering
with limited treatment options. In Europe, we are working to define
the regulatory pathway that we hope will enable us to get Oxbryta
to patients there. Outside of Europe, we are developing a strategy
to ensure long-term, sustainable access across the spectrum of
healthcare delivery systems, particularly in the complex and
underserved areas of Africa, Asia and South America.
While we still have a lot of work to do to achieve our long-term
goals, we are off to a promising start with the launch of Oxbryta
in the United States, and we feel we are on our way to realize our
vision of making SCD a well-managed chronic disease.
2019 was a major step forward, and our optimism for GBT’s future
carries over to 2020. We must acknowledge that in this current
year, we are navigating through an unprecedented time with the
COVID-19 pandemic. For GBT,
the health and safety of the sickle cell community and of our
employees are our highest priority. Proactively, we have taken
steps to support public health strategies designed to stem the
spread of the virus, including social distancing, while at the same
time working to ensure uninterrupted access for patients who are
prescribed Oxbryta and support for the entire sickle cell
Our entire team is driven by the same purpose: our commitment to
patients and the opportunity to change the lives of millions of
people around the world. I want to thank our shareholders – along
with the SCD community, our employees, clinical investigators,
practicing healthcare professionals, our business partners and our
Board of Directors – for the ongoing support of our company and our
With kind regards,
Ted W. Love, M.D.
President and Chief Executive Officer
Global Blood Therapeutics, Inc.
1. Food and Drug Administration press release, November 25,
2. Shah, N. et al. Plos One. 2019; 14(7): e0214355.
3. Global Blood Therapeutics press release, November 25, 2019.